{
    "clinical_study": {
        "@rank": "102397", 
        "acronym": "LUPSENIC", 
        "arm_group": {
            "arm_group_label": "Arsenic trioxide", 
            "arm_group_type": "Experimental", 
            "description": "Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day)."
        }, 
        "brief_summary": {
            "textblock": "Primary objectives :\n\n        -  To investigate the safety and the tolerability of ATO by IV infusions to patients with\n           SLE,\n\n        -  To determine the maximum tolerated dose of ATO.\n\n      Secondary objectives :\n\n        -  Evaluation of the clinical and biological response of the SLE to ATO,\n\n        -  Time of relapse in case of positive response,\n\n        -  Determination of the efficacy,\n\n        -  Pharmacokinetic study of ATO."
        }, 
        "brief_title": "Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Systemic Lupus", 
        "condition_browse": {
            "mesh_term": "Lupus Erythematosus, Systemic"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Systemic Lupus meeting the ACR (American College of Rheumatology) criteria,\n             progressive either SLEDAI activity score \u2265 4, despite a corticosteroid therapy \u2265 10\n             mg / d associated with hydroxychloroquine (in the absence of contraindication or\n             intolerance) and / or an immunosuppressive treatment at a stable dose,\n\n          -  Insured,\n\n          -  Availability for hospitalization required by the protocol (conventional and daily\n             hospitalizations).\n\n        Exclusion Criteria:\n\n          -  Inability to give their signed informed consent form,\n\n          -  Performans status > 2\n\n          -  QTcorrected space before treatment > 0.45 seconds\n\n          -  Hemoglobin less than 11g/dL\n\n          -  Neutrophils rate below 1 200 / mm3\n\n          -  Platelets rate below 100 Giga / mm3\n\n          -  Previous history of arrhythmia or heart rhythm disorder or other rhythm trouble by\n             referring cardiologist\n\n          -  Heart disorder (progressive pericarditis, valvular disease, ...) according to\n             cardiologist\n\n          -  Family previous history of arrhythmias\n\n          -  Taking drugs that potentially prolong the QT\n\n          -  Hypersensitivity to the active substance of Trisenox\u00ae or any of the excipients\n\n          -  Serum potassium \u2264 4 milliequivalent / L\n\n          -  Magnesemia \u2264 1,8 mg / dl\n\n          -  Increase corticosteroids beyond 20 mg / day within 15 days before inclusion\n\n          -  Immunosuppressive treatments, thalidomide introduced within the last 3 months\n\n          -  Biotherapy (rituximab, belimumab, ...) introduced within 6 months prior to inclusion\n\n          -  Pregnancy or lactation\n\n          -  For women of childbearing age, men and their partner : unless effective contraception\n             for the duration of participation in the study that is 7 months\n\n          -  Creatinine clearance <50 ml / min,\n\n          -  Hepatocellular insufficiency (TP <50%), and / or AST (aspartate aminotransferase) /\n             ALT (alanine aminotransferase) / ALP (alkaline phosphatase) > 2N\n\n          -  HBsAg positive, DNA detectable HbS\n\n          -  Infection with HIV, HBV (hepatitis B virus) or HCV (hepatitis C virus)\n\n          -  Renal or progressive central neurological impairment with possible alternative\n             therapeutic (to be discussed with the principal investigator and scientific board\n             meeting)\n\n          -  Peripheral neuropathy\n\n          -  Unweaned alcoholism\n\n          -  Minor\n\n          -  Patients older than 65 years\n\n          -  Patient having been professionally exposed to arsenic (cleaning electronic circuits\n             for example)\n\n          -  Guardianship patients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "13", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01738360", 
            "org_study_id": "RC12_0021", 
            "secondary_id": "2012-002259-40"
        }, 
        "intervention": {
            "arm_group_label": "Arsenic trioxide", 
            "description": "The study duration was 30 months (24 months recruitment + 6 months follow-up).Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day). The treatment should be administered by IV infusion over 2 hours of D1 to D4 (conventional hospitalization) and at D8, D11, D15, D18, D22 and D25. The protocol starts at the dose of 0.10 mg / kg / day. The stage at the dose of 0.075mg/kg/day is planned in case of toxicity with the first stage at the dose of 0.10mg/kg/day.\nThe course of study is as follows :\nPre-inclusion between D-35 and D-15\nTen injections during the first month distributed as follows : conventional hospitalization from D1 to D4 (one  injection per day) and daily hospitalization day for injections at D8, D11, D15, D18, D22 and D25.\nA telephone contact between D32 and D34\nA consultation at D40 then monthly consultation at D60, D90, D120, D150 and D180", 
            "intervention_name": "Arsenic trioxide", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Arsenic trioxide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Arsenic trioxide", 
            "Systemic Lupus", 
            "clinically", 
            "biologically active"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "contact": {
                "email": "mohamed.hamidou@chu-nantes.fr", 
                "last_name": "Mohamed HAMIDOU, Profesor", 
                "phone": "02 40 08 31 46"
            }, 
            "facility": {
                "address": {
                    "city": "Nantes", 
                    "country": "France", 
                    "zip": "44093"
                }, 
                "name": "Nantes University Hospital"
            }, 
            "investigator": {
                "last_name": "Mohamed HAMIDOU, Profesor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE)", 
        "overall_contact": {
            "email": "mohamed.hamidou@chu-nantes.fr", 
            "last_name": "Mohamed HAMIDOU, Profesor", 
            "phone": "02 40 08 31 46"
        }, 
        "overall_official": [
            {
                "affiliation": "CHU de Nantes", 
                "last_name": "Mohamed HAMIDOU, Profesor", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "AP-HP - La Piti\u00e9-Salp\u00e9tri\u00e8re", 
                "last_name": "Zahir AMOURA, Profesor", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "CHRU de Strasbourg", 
                "last_name": "Jean SIBILIA, Profesor", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University Hospital, Bordeaux", 
                "last_name": "Jean-Fran\u00e7ois VIALLARD, Profesor", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "CHU de Marseille", 
                "last_name": "Nicolas SCHLEINITZ, Profesor", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "CHRU de Lille", 
                "last_name": "Eric HACHULLA, Profesor", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France : ANSM - Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The definition of toxicity will be based on \"Common Terminology Criteria for Adverse Events, version 4\" of the U.S. Department of Health and Human Services, National Institutes of Health / National Cancer Institute.\nThe investigators will consider the occurrence of a significant toxicity if at least one of the following events is observed :\nAny symptomatic toxicity (and / or abnormality) cardiac and / or QTc prolongation > 480 msec.,\nApart from cardiac toxicity, toxicity of any grade 3 or 4 and irreversible toxicity (within 30 days) of any grade 1 or 2.", 
            "measure": "Cardiac adverse events whatever grade and any adverse event of grade 3 or 4", 
            "safety_issue": "Yes", 
            "time_frame": "30 days after the last infusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01738360"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Combined clinical response using the composite response of SLE or SRI (SLE Responder Index) (SLEDAI + BILAG (British Isles Lupus Assessment Group) + PGA) : a positive response is defined by a reduction of SELENA SLEDAI of at least 4 points, no worsening ( > 0,3 point) of the physician's global assessment (PGA), no new score \"A\" and no more than one new score \"B\" about BILAG. This composite index is now the benchmark tool for evaluating therapeutic protocols in SLE.", 
                "measure": "Composite response of SLE", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "The modification of anti-nuclear antibodies (ANA).", 
                "measure": "Anti-nuclear antibodies (ANA).", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "The modification of anti-native DNA.", 
                "measure": "Anti-native DNA", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "The modification of C3 complement.", 
                "measure": "C3 complement", 
                "safety_issue": "No", 
                "time_frame": "30 monhs"
            }, 
            {
                "description": "The modification of C4 complement.", 
                "measure": "C4 complement", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Analysis of Sedimentation rate.", 
                "measure": "Sedimentation rate", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Analysis of serum creatinine.", 
                "measure": "Serum creatinine", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Analysis of proteinuria/creatinuria ratio.", 
                "measure": "Proteinuria/creatinuria ratio", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Analysis of serum protein electrophoresis.", 
                "measure": "Serum protein electrophoresis", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Analysis of quantitation of immunoglobulins.", 
                "measure": "Quantitation of immunoglobulins", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Assessment of quality of life wih questionnaires SF36 and LupusQol.", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Reduction of the dose of steroids throughout the study.", 
                "measure": "Steroids", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Cessation of immunosuppressive treatments.", 
                "measure": "Immunosuppressive treatments", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Response time in case of positive response.", 
                "measure": "Response time", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Time to relapse in case of positive response.", 
                "measure": "Time to relapse", 
                "safety_issue": "No", 
                "time_frame": "30 months"
            }, 
            {
                "description": "Pharmacokinetic study of arsenic plasma with analysis of potential correlations blood rates/ toxicity and response.", 
                "measure": "Blood test of arsenic", 
                "safety_issue": "No", 
                "time_frame": "D1, D2, D3, D4, D8, D11, D15, D18, D22 and D25 (before and after each infusion)"
            }
        ], 
        "source": "Nantes University Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Medsenic Company", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Nantes University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}